



# Global Health L i m i t e d

**February 04, 2025**

**Ref:- GH/2024-25/EXCH/108**

The General Manager  
Dept. of Corporate Services  
BSE Limited,  
P J Towers, Dalal Street,  
Mumbai - 400 001

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051

**Scrip Code: 543654**

**Symbol: MEDANTA**

**Sub:** Press Release

Dear Sir(s),

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release, for the third quarter and nine months ended December 31, 2024 Results.

Kindly take the above on record.





Thanking you,

Yours faithfully

**For Global Health Limited**

**Rahul Ranjan**  
**Company Secretary & Compliance Officer**  
**M. No. A17035**

**Encl: a/a**



**Strong quarterly performance driven by consistent growth in patient volumes and higher contribution from developing hospitals**

**Total Income increased by 12.3% y-o-y to Rs. 9,595 million in Q3 FY25**

**EBITDA of Rs. 2,538 million, up by 8.4% y-o-y with the EBITDA margins at 26.5%**

**Net Profit of Rs. 1,429 million, up by 15.6% y-o-y with improved margin of 14.9%**

**Medanta will further strengthen its presence in Ranchi with a newly built 110-bedded hospital under a long-term lease agreement**

**Gurugram, February 04<sup>th</sup>, 2025:** Global Health Limited (NSE: [Medanta](#), BSE: [543654](#)), one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, today announced its unaudited consolidated financial results for the quarter ending 31<sup>st</sup> December, 2024.

**Consolidated Highlights: Q3 FY2025 vs. Q3 FY2024**

- Total income of Rs. 9,595 million, growth of 12.3% y-o-y
- EBITDA of Rs. 2,538 million, growth of 8.4% y-o-y with EBITDA margins at 26.5%
- Profit after tax of Rs. 1,429 million, growth of 15.6% y-o-y. PAT Margins increased to 14.9% compared to 14.5% in Q3 FY24
- Average occupied bed days increased by 10.5% y-o-y, representing an occupancy of 63.6% on increased bed capacity
- Average revenue per occupied bed (ARPOB) marginally grew by 1.2% y-o-y to Rs. 61,307
- In-patients count increased by 12.9% and Out-patient count increased by 8.7% y-o-y
- Matured hospitals revenue was Rs. 6,466 million, growth of 10.1% on y-o-y basis. EBITDA was Rs. 1,617 million, growth of 9.0% on y-o-y basis
- Developing hospitals revenue was INR 3,004 million, growth of 9.5% on y-o-y basis. EBITDA was INR 1,015 million, growth of 4.8% on y-o-y basis
- Revenue from international patients increased by 14.3% to y-o-y to Rs. 541 million
- Out-patient pharmacy (Hospital + Retail) continues to register strong growth. Revenue increased by 21.4% from INR 290 million in Q3 FY24 to INR 352 million in Q3 FY25

**Commenting on Q3 FY2025 results, Mr. Pankaj Sahni, Group CEO and Director said:**

"I am pleased to share that we have delivered a strong performance this quarter, driven by higher patient volumes and strong contributions from our developing hospitals.

Additionally, we are excited to announce our expansion into Ranchi with a new ~110-bed hospital under a long-term lease agreement. Strategically located just 1.2 km from our existing Medanta Ranchi hospital, the new facility enables seamless integration and operational synergies. This expansion will further strengthen our capacity to meet the growing healthcare needs in the region while raising the standard of healthcare delivery."

### **Board has approved signing of lease agreement for a newly built 110 bedded hospital in Ranchi**

- The Board of Directors has approved the signing of the lease agreement to operate and manage a newly built 110-bed hospital in Ranchi
- The hospital spans 1.33 acres with a constructed area of 108,000 sq. ft
- It has 110 operational beds and is equipped with an advanced OT setup and high-end medical equipment
- Medanta will enter into a 15-year long-term lease, extendable for two additional 15-year terms, at its sole discretion
- The hospital is expected to commence operations by the end of Q1 FY26
- Strategically located just 1.2 km from Medanta Ranchi existing hospital, the new facility enables seamless integration and operational synergies
- Designed primarily for high-end tertiary care, will address a critical gap currently unmet at Medanta Ranchi

### **Key Quarterly Developments – Q3 FY2025**

- Medanta Lucknow sets a **new benchmark for most robotic surgeries in first 90 days**, performing 30 robotic gynecological surgeries in 76 days
- Medanta Lucknow completes **50+ Robotic Da Vinci XI surgeries**
- Medanta Gurugram's multi-speciality team successfully performs a **neuro-intervention on a newborn with Choroidal Vein of Galen Malformation**, a rare condition requiring a highly precise procedure that **available at only a few centers globally**
- Medanta Gurugram successfully addresses a **complex case of peripheral arterial disease with Stealth Orbital 360 Atherectomy**, setting a new standard of care, with a focus on re-intervention if needed in a 'leave no metal behind' approach
- During the quarter, 34 beds were added across facilities, increasing the total additions to 219 beds in 9M FY25
- Medanta has on boarded 49 doctors across facilities during the quarter, taking a total of 101 new doctors in 9M FY25

**Financial Highlights: Q3 and 9M FY2025**

INR million	Nine Months End			Quarter				
	9M FY24	9M FY25	Y-o-Y Growth %	Q3 FY24	Q2 FY25	Q3 FY25	Y-o-Y Growth %	Q-o-Q Growth %
<b>Revenue from operations</b>	<b>24,665</b>	<b>27,611</b>	<b>11.9%</b>	<b>8,365</b>	<b>9,566</b>	<b>9,434</b>	<b>12.8%</b>	<b>(1.4)%</b>
Other income	472	562	18.9%	181	182	160	(11.4)%	(12.0)%
<b>Total income</b>	<b>25,137</b>	<b>28,172</b>	<b>12.1%</b>	<b>8,545</b>	<b>9,748</b>	<b>9,595</b>	<b>12.3%</b>	<b>(1.6)%</b>
Cost of materials consumed	5,656	6,661	17.8%	1,907	2,280	2,292	20.2%	0.5%
Employee benefits expense	8,660	9,862	13.9%	2,967	3,366	3,300	11.2%	(2.0)%
Other expenses	4,151	4,564	9.9%	1,331	1,637	1,465	10.1%	(10.5)%
<b>EBITDA</b>	<b>6,670</b>	<b>7,085</b>	<b>6.2%</b>	<b>2,340</b>	<b>2,465</b>	<b>2,538</b>	<b>8.4%</b>	<b>3.0%</b>
<b>EBITDA Margins %</b>	<b>26.5%</b>	<b>25.2%</b>	<b>(138) bps</b>	<b>27.4%</b>	<b>25.3%</b>	<b>26.5%</b>	<b>(94) bps</b>	<b>116 bps</b>
Finance costs	557	502	(9.8)%	177	160	163	(7.9)%	1.9%
Depreciation and amortisation expense	1,273	1,445	13.5%	440	494	484	10.1%	(2.0)%
<b>Profit before tax</b>	<b>4,840</b>	<b>5,138</b>	<b>6.2%</b>	<b>1,724</b>	<b>1,811</b>	<b>1,891</b>	<b>9.7%</b>	<b>4.4%</b>
Tax expenses	1,333	1,339	0.4%	488	503	462	(5.4)%	(8.1)%
<b>Profit after tax</b>	<b>3,507</b>	<b>3,799</b>	<b>8.3%</b>	<b>1,235</b>	<b>1,308</b>	<b>1,429</b>	<b>15.6%</b>	<b>9.2%</b>

*Note: Previous period figures have been regrouped/reclassified to conform to the current period's classification*

\*\*\*\*\*

**About Global Health Limited (Medanta)**

Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third- and fourth-highest civilian awards in India, and the Dr. B.C. Roy Award in recognition of his distinguished contribution to medicine.

Global Health Limited (the "Company") is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, with key specialties cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology, according to the report titled "An assessment of the healthcare delivery market in India, September 2022" by CRISIL Limited.

Under the "Medanta" brand, the Company has a network of five hospitals currently in operation (Gurgaon, Indore, Ranchi, Lucknow, and Patna). Spanning an area of 4.7 million sq. ft., its operational hospitals have 3,042 installed beds as on December 31, 2024. It also has one hospital under-construction in Noida. The Company provides healthcare services in over 30 medical specialties and engages over 1,800+ doctors led by highly experienced department heads.

For more information visit [www.medanta.org](http://www.medanta.org) or contact:

**Global Health Limited**

**Ravi Gothwal**

[ravi.gothwal@medanta.org](mailto:ravi.gothwal@medanta.org)

Tel: 0124 – 4141 414

**Bhushan Khandelwal**

[bhushan.khandelwal@medanta.org](mailto:bhushan.khandelwal@medanta.org)

Tel: 0124 – 4141 414

**Safe Harbour Disclaimer**

This press release, apart from historical information, contains some "forward-looking statements" including those describing the Company's strategies, strategic direction, objectives, future prospects, estimates etc. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by these statements. These factors include, but are not limited to general market conditions, macro-economic, movements in currency exchange and interest rates, the ability to attract and retain high quality human resource, competitive pressures, technological developments, governmental and regulatory trends, legislative developments, and other key factors beyond the control of the Company.

These forward looking statements are based on information currently available to us, and we assume no obligation to revise these statements as circumstances change. The Company may alter, modify or otherwise change in any manner the content of Presentation/Press Release, without obligation to notify any person of such revision or changes.